Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors

Journal Article · · Bioorg. Med. Chem. Lett.
Starting from quinazoline 3a, we designed potent and selective ALK5 inhibitors over p38MAP kinase from a rational drug design approach based on co-crystal structures in the human ALK5 kinase domain. The quinazoline 3d exhibited also in vivo activity in an acute rat model of DMN-induced liver fibrosis when administered orally at 5 mg/kg (bid).
Research Organization:
Argonne National Laboratory (ANL)
Sponsoring Organization:
USDOE
OSTI ID:
1005727
Journal Information:
Bioorg. Med. Chem. Lett., Journal Name: Bioorg. Med. Chem. Lett. Journal Issue: (8) ; 04, 2009 Vol. 19; ISSN 0960-894X
Country of Publication:
United States
Language:
ENGLISH

Similar Records

Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation
Journal Article · Thu Jun 01 00:00:00 EDT 2017 · Bioorganic and Medicinal Chemistry Letters · OSTI ID:1404982

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Journal Article · Mon Jan 11 23:00:00 EST 2010 · Nature · OSTI ID:1006040

Pyrazolo-Pyrimidines: A Novel Heterocyclic Scaffold for Potent and Selective p38alpha Inhibitors
Journal Article · Mon Dec 31 23:00:00 EST 2007 · BioOrganic and Medicinal Chemistry Letters · OSTI ID:959850